Literature DB >> 11087679

Purification of GSK-3 by affinity chromatography on immobilized axin.

A Primot1, B Baratte, M Gompel, A Borgne, S Liabeuf, J L Romette, E H Jho, F Costantini, L Meijer.   

Abstract

Glycogen synthase kinase 3 (GSK-3), an element of the Wnt signalling pathway, plays a key role in numerous cellular processes including cell proliferation, embryonic development, and neuronal functions. It is directly involved in diseases such as cancer (by controlling apoptosis and the levels of beta-catenin and cyclin D1), Alzheimer's disease (tau hyperphosphorylation), and diabetes (as a downstream element of insulin action, GSK-3 regulates glycogen and lipid synthesis). We describe here a rapid and efficient method for the purification of GSK-3 by affinity chromatography on an immobilized fragment of axin. Axin is a docking protein which interacts with GSK-3ss, beta-catenin, phosphatase 2A, and APC. A polyhistidine-tagged axin peptide (residues 419-672) was produced in Escherichia coli and either immobilized on Ni-NTA agarose beads or purified and immobilized on CNBr-activated Sepharose 4B. These "Axin-His6" matrices were found to selectively bind recombinant rat GSK-3 beta and native GSK-3 from yeast, sea urchin embryos, and porcine brain. The affinity-purified enzymes displayed high kinase activity. This single step purification method provides a convenient tool to follow the status of GSK-3 (protein level, phosphorylation state, kinase activity) under various physiological settings. It also provides a simple and efficient way to purify large amounts of active recombinant or native GSK-3 for screening purposes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087679     DOI: 10.1006/prep.2000.1321

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  21 in total

1.  Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus.

Authors:  Lilia Topol; Wen Chen; Hai Song; Timothy F Day; Yingzi Yang
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

2.  Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.

Authors:  Julien Debray; Simon Bonte; Olivier Lozach; Laurent Meijer; Martine Demeunynck
Journal:  Mol Divers       Date:  2012-09-19       Impact factor: 2.943

3.  A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways.

Authors:  Xiao Sun; Xiao-Bin Zhuo; Yi-Ping Hu; Xuan Zheng; Qing-Jie Zhao
Journal:  Mol Cell Biochem       Date:  2018-03-12       Impact factor: 3.396

4.  Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8.

Authors:  Katy Billot; Charlène Coquil; Benoit Villiers; Béatrice Josselin-Foll; Nathalie Desban; Claire Delehouzé; Nassima Oumata; Yannick Le Meur; Alessandra Boletta; Thomas Weimbs; Melanie Grosch; Ralph Witzgall; Sophie Saunier; Evelyne Fischer; Marco Pontoglio; Alain Fautrel; Michal Mrug; Darren Wallace; Pamela V Tran; Marie Trudel; Nikolay Bukanov; Oxana Ibraghimov-Beskrovnaya; Laurent Meijer
Journal:  Am J Physiol Renal Physiol       Date:  2018-03-14

5.  New 5-ylidene rhodanine derivatives based on the dispacamide A model.

Authors:  Solene Guiheneuf; Ludovic Paquin; François Carreaux; Emilie Durieu; Thierry Roisnel; Laurent Meijer; Jean-Pierre Bazureau
Journal:  Mol Divers       Date:  2014-03-02       Impact factor: 2.943

6.  Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.

Authors:  Konstantina Vougogiannopoulou; Yoan Ferandin; Karima Bettayeb; Vassilios Myrianthopoulos; Olivier Lozach; Yunzhen Fan; Carl Hirschie Johnson; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Emmanuel Mikros; Laurent Meijer
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

7.  10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Authors:  Hannes Falke; Apirat Chaikuad; Anja Becker; Nadège Loaëc; Olivier Lozach; Samira Abu Jhaisha; Walter Becker; Peter G Jones; Lutz Preu; Knut Baumann; Stefan Knapp; Laurent Meijer; Conrad Kunick
Journal:  J Med Chem       Date:  2015-03-23       Impact factor: 7.446

Review 8.  Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.

Authors:  Nadège Loaëc; Eletta Attanasio; Benoît Villiers; Emilie Durieu; Tania Tahtouh; Morgane Cam; Rohan A Davis; Aline Alencar; Mélanie Roué; Marie-Lise Bourguet-Kondracki; Peter Proksch; Emmanuelle Limanton; Solène Guiheneuf; François Carreaux; Jean-Pierre Bazureau; Michelle Klautau; Laurent Meijer
Journal:  Mar Drugs       Date:  2017-10-17       Impact factor: 5.118

9.  Anticancer alkaloid lamellarins inhibit protein kinases.

Authors:  Dianne Baunbaek; Nolwenn Trinkler; Yoan Ferandin; Olivier Lozach; Poonsakdi Ploypradith; Somsak Rucirawat; Fumito Ishibashi; Masatomo Iwao; Laurent Meijer
Journal:  Mar Drugs       Date:  2008-10-07       Impact factor: 5.118

10.  Synthesis of New N,N'-Bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)piperazine Derivatives Under Microwave Irradiation and Preliminary Biological Evaluation.

Authors:  Wacothon Karime Coulibaly; Ludovic Paquin; Anoubilé Bénié; Yves-Alain Bekro; Emilie Durieux; Laurent Meijer; Rémy Le Guével; Anne Corlu; Jean-Pierre Bazureau
Journal:  Sci Pharm       Date:  2012-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.